Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of NeuroSense Therapeutics Ltd. from 31 Dec 2020 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
NeuroSense Therapeutics Ltd. quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents in USD history and change rate from 31 Dec 2020 to 30 Jun 2025.
  • NeuroSense Therapeutics Ltd. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents for the quarter ending 30 Jun 2025 was $666,000, a 45% decline year-over-year.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, YoY Quarterly Change (%)

NeuroSense Therapeutics Ltd. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $666,000 -$542,000 -45% 30 Jun 2025 6-K 01 Aug 2025 2025 Q2
Q4 2024 $3,378,000 +$738,000 +28% 31 Dec 2024 6-K 01 Aug 2025 2025 Q2
Q2 2024 $1,208,000 -$5,881,000 -83% 30 Jun 2024 6-K 01 Aug 2025 2025 Q2
Q4 2023 $2,640,000 -$903,000 -25% 31 Dec 2023 6-K 01 Aug 2025 2025 Q2
Q2 2023 $7,089,000 30 Jun 2023 6-K 30 Sep 2024 2024 Q2
Q4 2022 $3,543,000 -$7,520,000 -68% 31 Dec 2022 20-F 07 Apr 2025 2024 FY
Q4 2021 $11,063,000 +$10,364,000 +1483% 31 Dec 2021 20-F 07 Apr 2025 2024 FY
Q4 2020 $699,000 31 Dec 2020 6-K 17 Jun 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.